Internal Medicine

RheumMadness

RheumMadness

Questions discussed in this category

Are there certain patients in whom you would avoid initiation of ULT during an acute gout flare?

This question is part of a collaboration with RheumMadness and is specifically in reference to: ULT During Gout Flare.

3 Answers available

What is your approach to practical monitoring of lupus disease activity in clinical practice?

What disease activity index do you find more useful and most practical in a busy clinical setting? How often do you assess it?This question is part of...

1 Answer available

How do you approach follow up of young patients with isolated +ANA, but no current clinical signs or symptoms of SLE?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Antibodies Before SLE.

6 Answers available

Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?

This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).

2 Answers available

Do you generally recommend starting nintedanib prior to immunosuppressive therapy in a patient with CTD-ILD?

Do you prefer to start with nintedanib and then add immunosuppressive agents, or give a trial of immunosuppressive medication first, then add nintedan...

4 Answers available

Do you ever consider discontinuing hydroxychloroquine in patients with SLE in longstanding remission except in cases of overt toxicity?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Hydroxychloroquine Withdrawal.

2 Answers available

Do you use IL-1 inhibitors to prevent flares of gout or CPPD in patients who experience flares despite prophylaxis with colchicine, NSAIDs, and/or low-dose prednisone?

2 Answers available

How can ethnic representation in clinical research studies in childhood and adult SLE be improved?

This question is part of a collaboration with RheumMadness and is specifically in reference to: EMBRACE

2 Answers available

How do you counsel patients who ask if there are any dietary modifications they can make to help control their autoimmune disease?

This question is part of a collaboration with RheumMadness and is specifically in reference to: ADIRA Diet

1 Answer available

Papers discussed in this category

Ann. Rheum. Dis., 2018 Apr 25

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Rheum Dis Clin North Am, 2022 Feb

Disparities in Pediatric Rheumatic Diseases.

Arthritis Care Res (Hoboken), 2020 Aug 19

Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications.

Ann Rheum Dis, 2014 Feb 13

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.

Ann Rheum Dis, 2021 Dec 15

Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Lupus Sci Med, 2021 Apr

Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre.

Arthritis Res Ther, 2006

Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus.

Adv Biomed Res, 2016 Aug 30

The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition.

Lupus, 2022 Mar 25

Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.

The New England journal of medicine, 2003-10-16

Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Rheumatology (Oxford, England), 2018-09-01

The SLE-key test serological signature: new insights into the course of lupus.

Lupus, 2021 Jan 05

Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort.

Arthritis Rheumatol, 2018 Jun 27

Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015.

J Manag Care Spec Pharm, 2022 Jul 01

Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.

Diagnostics (Basel), 2021 Sep 01

Anti-DFS70 Antibodies for Differentiating Systemic Autoimmune Rheumatic Disease in Patients with Positive ANA Tests: A Systematic Review and Meta-Analysis.

Front Immunol, 2021 May 27

Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond.

Chest, 2021 Feb

Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.

Expert review of clinical immunology, 2015 Dec 22

Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations.

The neurologist, 2017 Jul

Spectrum of Autonomic Nervous System Impairment in Sjögren Syndrome.

Arthritis research & therapy, 2013-02-01

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

Arthritis Rheumatol, 2021 Jul 07

A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.

Ann Rheum Dis, 2012 May 14

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.

Mol Biol Rep, 2021 Jun 01

The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease.

Curr Rheumatol Rep, 2014 Feb

Anti-interleukin-1 therapy in the management of gout.

Pharmacotherapy, 2013 Apr 03

Role of interleukin-1 inhibitors in the management of gout.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Clinical journal of the American Society of Nephrology : CJASN, 2017-05-08

Update on Lupus Nephritis.

Annals of the rheumatic diseases, 2023 Oct 12

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

Arthritis & rheumatology (Hoboken, N.J.), 2023 Jun 25

"Burnout" Coupled with Workforce Shortages Spells Trouble: Innovative Solutions Are Essential for More Satisfying Rheumatology Practice.

Modern rheumatology, 2020 Jun 16

Which is the best SLE activity index for clinical trials?

Arthritis care & research, 2023 Nov 28

Reference Range of Hydroxychloroquine Blood Levels That Can Reduce Odds of Active Lupus and Prevent Flares.

Related Topics in Internal Medicine